You are here: Simmaron ResearchDonate

Simmaron Responds to COVID-19 Health Emergency!

Testing, testing, testing: Simmaron fills an urgent community need for COVID-19 testing in the Tahoe area, working in collaboration with long-time partner Coppe Laboratories. Essential workers, patients and the Tahoe community benefit from wider testing.

Simmaron’s work on COVID-19 testing will also provide a research bridge to link longtime post-viral ME/CFS research with a new viral pandemic that poses the unfortunate prospect of inflicting many more patients with chronic, post-viral disease. We have so much to learn from each other: as we study post-COVID recovery, new post-viral patients can learn from long-time post-viral patients and vice versa.


See most recent PRESS RELEASE here: SRI_PressRelease_COVID19_052720


Simmaron Powers Change in 2019!

Click here: SRI 2019 Review & 2020 Prospectus

Simmaron Powers Change in 2018!

  • Commenced Ampligen Responder Research Study in collaboration with Cornell University, to study measures of response and patient selection in our quest for FDA approval of ME/CFS treatments!
  • Obtained rare Levine specimen samples from early years of ME/CFS outbreak to propel future research!
  • Published 1 new peer-reviewed manuscript in collaboration with Columbia, and have additional manuscripts with spinal fluid findings in submission process
  • Collaborator in NIH funded Collaborative Research Center grants
  • Continued collaborations with CDC, Columbia Univ., Cornell Univ., SUNY Albany, and NIH Intramural Study
  • Served on CFSAC’s Treatment Trial Working Group, until CFSAC’s untimely disbanding

Simmaron Powers Change in 2017!

  • Collaborator in NIH funded Collaborative Research Center grant!
  • Published 3 new peer-reviewed manuscripts about findings in ME/CFS with collaborators, including identification of 2 disease subsets.
  • 16 total publications in scientific journals in 6 years!
  • Preparing publications on results of Phase 2 of our signature Spinal Fluid study for 2018
  • Continued collaborations with CDC, Columbia Univ., SUNY Albany, and NIH Intramural Study
  • Continued data extraction projects to examine potential treatments
  • Served on the U.S. Secretary of Health’s Chronic Fatigue Syndrome Advisory Committee (CFSAC)

Simmaron Powers Change in 2016!

  • Simmaron celebrates 5 year anniversary of strategic, game-changing research that is refocusing ME/CFS science on immunity
  • Dr. Daniel Peterson advises NIH on the NIH Clinical Center study of Post Infectious ME/CFS
  • Collaborating with Columbia University on a refined Phase 2 of our Spinal Fluid study, seeking in part to replicate the recent Naviaux finding of a hypometabolic state similar to “dauer” or hibernation
  • Collaborating with Columbia on an exercise intolerance study
  • Completed year 4 of the large CDC multi-site clinical study
  • Pursuing data analysis of the effects of treatments among Dr. Peterson’s patients
  • Continuing Arthropod study to identify vector-borne pathogen exposure among patients and controls

Simmaron Powers Change in 2015!

  • Expanding research collaboration with Columbia University
  • Published Simmaron’s Signature Spinal Fluid Studies with Columbia University
  • Columbia publications contribute to renewal of NIH research program
  • Began Phase 2 of Columbia Spinal Fluid study
  • Extracted clinical data to document how Ampligen works in Dr. Peterson’s clinic
  • Completed our portion of Columbia Microbiome study
  • Completed our portion of Albany auto-immunity study
  • Completed year 3 of CDC multi-site clinical study

You Power Simmaron’s Results in 2014!

  • Secured partnership with Columbia University to run our Physician Fellowship, collaborating with Dr. Peterson to train doctors in ME/CFS
  • Hosted Immunology Panel at IACFS/ME Conference, which made immunological testing recommendations for the medical community
  • Simmaron’s Scientific Director won 2 NIH grants to study immune abnormalities in ME/CFS
  • Completed our part of CDC and Columbia study extensions
  • Presented at HHV6 Conference on Dr. Peterson’s experience using Vistide (cidofovir) for ME/CFS

    Simmaron Research | Give | Donate | Scientifically Redefining ME/CFS

Invest in Simmaron’s Exciting Pilot Studies!

  • Data Extraction Studies: Simmaron has unparalleled data from Dr. Peterson’s clinical experience monitoring immune testing and utilizing immune-based treatments. We seek funding to extract and statistically analyze clinical experience with treatments to publish data that will stimulate more clinical trials in ME/CFS. Collaborators:  Sierra Internal Medicine. Cost: $100,000 for 2018.

Friends and Supporters:

Rich Carson, ProHealth Founder                         Llewellyn King, ME/CFS Alert                    Cort Johnson’s Health Rising


Simmaron Research Inc. is a Nevada non-profit, 501(c)3. Your contribution is tax deductible to the full extent allowed by law. Restricted donations will fund indirect costs in the amount of 10%.